Review



high molecular weight hmw poly i c  (InvivoGen)


Bioz Verified Symbol InvivoGen is a verified supplier
Bioz Manufacturer Symbol InvivoGen manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    InvivoGen high molecular weight hmw poly i c
    High Molecular Weight Hmw Poly I C, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 5763 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/high molecular weight hmw poly i c/product/InvivoGen
    Average 97 stars, based on 5763 article reviews
    high molecular weight hmw poly i c - by Bioz Stars, 2026-02
    97/100 stars

    Images



    Similar Products

    97
    InvivoGen high molecular weight hmw poly i c
    High Molecular Weight Hmw Poly I C, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/high molecular weight hmw poly i c/product/InvivoGen
    Average 97 stars, based on 1 article reviews
    high molecular weight hmw poly i c - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    97
    InvivoGen high molecular weight poly i c
    High Molecular Weight Poly I C, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/high molecular weight poly i c/product/InvivoGen
    Average 97 stars, based on 1 article reviews
    high molecular weight poly i c - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    97
    InvivoGen high molecular weight poly i c pic
    High Molecular Weight Poly I C Pic, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/high molecular weight poly i c pic/product/InvivoGen
    Average 97 stars, based on 1 article reviews
    high molecular weight poly i c pic - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    96
    InvivoGen high molecular weight hmw vaccigrade poly i c
    A Timeline for mating and treatment of human STAT2 knock-in (hSTAT2 KI) mice with high molecular weight polyinosinic-polycytidylic acid <t>(HMW</t> <t>poly(I:C)).</t> Created in BioRender. Jurado, K. (2025) https://BioRender.com/eegilr9 . B Serum IL-6 levels in PBS- and HMW Poly(I:C)-treated dams at 6 h post-injection as determined via ELISA. n = 3 dams per group. Statistical analysis performed via ordinary two-way ANOVA, **p < 0.01, ns= not significant (From left, p = >0.9999, 0.0013, 0.0011, 0.9896). Data presented as mean values ± SD. C Proportion of fetuses exhibiting healthy, early resorption, or total resorption phenotypes at E13.5 in PBS- and HMW Poly(I:C)-treated dams. Graph displays total number of fetuses from 3-4 litters per condition. D Representative images depicting fetal outcomes at E13.5. Phenotypes were determined for each fetus based on gross morphology and tissue integrity, as described in methods. E Timeline for mating and infection of hSTAT2 KI mice, as described in methods. Created in BioRender. Jurado, K. (2025) https://BioRender.com/m1xcoc2 . F Proportion of fetuses exhibiting healthy, early resorption, or total resorption phenotypes at E13.5 in PBS- and ZIKV-infected dams. Fetal outcomes were evaluated in 3 independent litters for all conditions except ZIKV-infected IL27RA −/− dams, for which 4 independent litters were evaluated. Graph displays total number of fetuses per condition. G–I ZIKV burdens at E13.5 as determined via quantitative RT-PCR. G Combined ZIKV burden of one matching fetus and placenta, normalized to combined tissue weight. Shape of data point represents observed fetal phenotype. Total number of fetal/placental units per condition plotted (see 4 F ). Statistical analysis performed via Kruskal-Wallis ANOVA, ***p < 0.001, ns=not significant (From left, p = >0.9999, 0.0006). H Left: Fetal ZIKV burdens, normalized to fetus weights. Viral burdens for subset of fetuses exhibiting “healthy” phenotypes plotted (Isotype n = 24, α-IL-27 n = 16, IL27RA −/− n = 28). Right: Placental ZIKV burdens, normalized to placental weights. Viral burdens of placentas matched to fetuses with “healthy” phenotypes plotted (Isotype n = 24, α-IL-27 n = 16, IL27RA −/− n = 28). Statistical analysis performed via Kruskal-Wallis ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns=not significant (Fetal from left, p = >0.9999, 0.0374; Placental from left, p = 0.0378, <0.0001). I Maternal serum ZIKV burdens, normalized to serum weight. n = 3 dams for Isotype and α-IL-27-treated groups, n = 4 IL27RA −/− dams. Not significant via Kruskal-Wallis ANOVA.
    High Molecular Weight Hmw Vaccigrade Poly I C, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/high molecular weight hmw vaccigrade poly i c/product/InvivoGen
    Average 96 stars, based on 1 article reviews
    high molecular weight hmw vaccigrade poly i c - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    97
    InvivoGen poly i c high molecular weight
    A Timeline for mating and treatment of human STAT2 knock-in (hSTAT2 KI) mice with high molecular weight polyinosinic-polycytidylic acid <t>(HMW</t> <t>poly(I:C)).</t> Created in BioRender. Jurado, K. (2025) https://BioRender.com/eegilr9 . B Serum IL-6 levels in PBS- and HMW Poly(I:C)-treated dams at 6 h post-injection as determined via ELISA. n = 3 dams per group. Statistical analysis performed via ordinary two-way ANOVA, **p < 0.01, ns= not significant (From left, p = >0.9999, 0.0013, 0.0011, 0.9896). Data presented as mean values ± SD. C Proportion of fetuses exhibiting healthy, early resorption, or total resorption phenotypes at E13.5 in PBS- and HMW Poly(I:C)-treated dams. Graph displays total number of fetuses from 3-4 litters per condition. D Representative images depicting fetal outcomes at E13.5. Phenotypes were determined for each fetus based on gross morphology and tissue integrity, as described in methods. E Timeline for mating and infection of hSTAT2 KI mice, as described in methods. Created in BioRender. Jurado, K. (2025) https://BioRender.com/m1xcoc2 . F Proportion of fetuses exhibiting healthy, early resorption, or total resorption phenotypes at E13.5 in PBS- and ZIKV-infected dams. Fetal outcomes were evaluated in 3 independent litters for all conditions except ZIKV-infected IL27RA −/− dams, for which 4 independent litters were evaluated. Graph displays total number of fetuses per condition. G–I ZIKV burdens at E13.5 as determined via quantitative RT-PCR. G Combined ZIKV burden of one matching fetus and placenta, normalized to combined tissue weight. Shape of data point represents observed fetal phenotype. Total number of fetal/placental units per condition plotted (see 4 F ). Statistical analysis performed via Kruskal-Wallis ANOVA, ***p < 0.001, ns=not significant (From left, p = >0.9999, 0.0006). H Left: Fetal ZIKV burdens, normalized to fetus weights. Viral burdens for subset of fetuses exhibiting “healthy” phenotypes plotted (Isotype n = 24, α-IL-27 n = 16, IL27RA −/− n = 28). Right: Placental ZIKV burdens, normalized to placental weights. Viral burdens of placentas matched to fetuses with “healthy” phenotypes plotted (Isotype n = 24, α-IL-27 n = 16, IL27RA −/− n = 28). Statistical analysis performed via Kruskal-Wallis ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns=not significant (Fetal from left, p = >0.9999, 0.0374; Placental from left, p = 0.0378, <0.0001). I Maternal serum ZIKV burdens, normalized to serum weight. n = 3 dams for Isotype and α-IL-27-treated groups, n = 4 IL27RA −/− dams. Not significant via Kruskal-Wallis ANOVA.
    Poly I C High Molecular Weight, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/poly i c high molecular weight/product/InvivoGen
    Average 97 stars, based on 1 article reviews
    poly i c high molecular weight - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    Image Search Results


    A Timeline for mating and treatment of human STAT2 knock-in (hSTAT2 KI) mice with high molecular weight polyinosinic-polycytidylic acid (HMW poly(I:C)). Created in BioRender. Jurado, K. (2025) https://BioRender.com/eegilr9 . B Serum IL-6 levels in PBS- and HMW Poly(I:C)-treated dams at 6 h post-injection as determined via ELISA. n = 3 dams per group. Statistical analysis performed via ordinary two-way ANOVA, **p < 0.01, ns= not significant (From left, p = >0.9999, 0.0013, 0.0011, 0.9896). Data presented as mean values ± SD. C Proportion of fetuses exhibiting healthy, early resorption, or total resorption phenotypes at E13.5 in PBS- and HMW Poly(I:C)-treated dams. Graph displays total number of fetuses from 3-4 litters per condition. D Representative images depicting fetal outcomes at E13.5. Phenotypes were determined for each fetus based on gross morphology and tissue integrity, as described in methods. E Timeline for mating and infection of hSTAT2 KI mice, as described in methods. Created in BioRender. Jurado, K. (2025) https://BioRender.com/m1xcoc2 . F Proportion of fetuses exhibiting healthy, early resorption, or total resorption phenotypes at E13.5 in PBS- and ZIKV-infected dams. Fetal outcomes were evaluated in 3 independent litters for all conditions except ZIKV-infected IL27RA −/− dams, for which 4 independent litters were evaluated. Graph displays total number of fetuses per condition. G–I ZIKV burdens at E13.5 as determined via quantitative RT-PCR. G Combined ZIKV burden of one matching fetus and placenta, normalized to combined tissue weight. Shape of data point represents observed fetal phenotype. Total number of fetal/placental units per condition plotted (see 4 F ). Statistical analysis performed via Kruskal-Wallis ANOVA, ***p < 0.001, ns=not significant (From left, p = >0.9999, 0.0006). H Left: Fetal ZIKV burdens, normalized to fetus weights. Viral burdens for subset of fetuses exhibiting “healthy” phenotypes plotted (Isotype n = 24, α-IL-27 n = 16, IL27RA −/− n = 28). Right: Placental ZIKV burdens, normalized to placental weights. Viral burdens of placentas matched to fetuses with “healthy” phenotypes plotted (Isotype n = 24, α-IL-27 n = 16, IL27RA −/− n = 28). Statistical analysis performed via Kruskal-Wallis ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns=not significant (Fetal from left, p = >0.9999, 0.0374; Placental from left, p = 0.0378, <0.0001). I Maternal serum ZIKV burdens, normalized to serum weight. n = 3 dams for Isotype and α-IL-27-treated groups, n = 4 IL27RA −/− dams. Not significant via Kruskal-Wallis ANOVA.

    Journal: Nature Communications

    Article Title: Interleukin-27 is antiviral against Zika virus at the maternal-fetal interface

    doi: 10.1038/s41467-025-67378-0

    Figure Lengend Snippet: A Timeline for mating and treatment of human STAT2 knock-in (hSTAT2 KI) mice with high molecular weight polyinosinic-polycytidylic acid (HMW poly(I:C)). Created in BioRender. Jurado, K. (2025) https://BioRender.com/eegilr9 . B Serum IL-6 levels in PBS- and HMW Poly(I:C)-treated dams at 6 h post-injection as determined via ELISA. n = 3 dams per group. Statistical analysis performed via ordinary two-way ANOVA, **p < 0.01, ns= not significant (From left, p = >0.9999, 0.0013, 0.0011, 0.9896). Data presented as mean values ± SD. C Proportion of fetuses exhibiting healthy, early resorption, or total resorption phenotypes at E13.5 in PBS- and HMW Poly(I:C)-treated dams. Graph displays total number of fetuses from 3-4 litters per condition. D Representative images depicting fetal outcomes at E13.5. Phenotypes were determined for each fetus based on gross morphology and tissue integrity, as described in methods. E Timeline for mating and infection of hSTAT2 KI mice, as described in methods. Created in BioRender. Jurado, K. (2025) https://BioRender.com/m1xcoc2 . F Proportion of fetuses exhibiting healthy, early resorption, or total resorption phenotypes at E13.5 in PBS- and ZIKV-infected dams. Fetal outcomes were evaluated in 3 independent litters for all conditions except ZIKV-infected IL27RA −/− dams, for which 4 independent litters were evaluated. Graph displays total number of fetuses per condition. G–I ZIKV burdens at E13.5 as determined via quantitative RT-PCR. G Combined ZIKV burden of one matching fetus and placenta, normalized to combined tissue weight. Shape of data point represents observed fetal phenotype. Total number of fetal/placental units per condition plotted (see 4 F ). Statistical analysis performed via Kruskal-Wallis ANOVA, ***p < 0.001, ns=not significant (From left, p = >0.9999, 0.0006). H Left: Fetal ZIKV burdens, normalized to fetus weights. Viral burdens for subset of fetuses exhibiting “healthy” phenotypes plotted (Isotype n = 24, α-IL-27 n = 16, IL27RA −/− n = 28). Right: Placental ZIKV burdens, normalized to placental weights. Viral burdens of placentas matched to fetuses with “healthy” phenotypes plotted (Isotype n = 24, α-IL-27 n = 16, IL27RA −/− n = 28). Statistical analysis performed via Kruskal-Wallis ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns=not significant (Fetal from left, p = >0.9999, 0.0374; Placental from left, p = 0.0378, <0.0001). I Maternal serum ZIKV burdens, normalized to serum weight. n = 3 dams for Isotype and α-IL-27-treated groups, n = 4 IL27RA −/− dams. Not significant via Kruskal-Wallis ANOVA.

    Article Snippet: To mimic immune activation during viral infection, High Molecular Weight (HMW) Vaccigrade Poly(I:C) (Invivogen, vac-pic) was delivered to pregnant mice at E6.5 via intraperitoneal injection at 20 mg/kg.

    Techniques: Knock-In, High Molecular Weight, Injection, Enzyme-linked Immunosorbent Assay, Infection, Quantitative RT-PCR